Oxford Biomedica CEO on Covid-19 Vaccine, Industry Outlook

The transcript discusses the manufacturing process of a vaccine, highlighting the challenges and financial risks involved. It explores partnerships with companies like AstraZeneca and the impact of the pandemic on core business operations. The balance between gene therapy and manufacturing services is examined, along with the diversification of partnerships and future growth potential in the industry.

What insights can you provide about the current manufacturing process of the vaccine?

What role does your company play in the global effort to combat the pandemic?

Can you explain the financial risks associated with the production of the vaccine?

How has the pandemic affected your partnerships and business operations?

What are the key factors to consider in gene therapy manufacturing?

What strategies have you implemented to diversify your partnerships?

How do you foresee the growth of the gene and cell therapy sector in the future?